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Abstract
Hepatosplenic T-cell lymphoma (HSTCL) is an extremely rare 
and aggressive form of non-Hodgkin lymphoma associated 
with poor response to treatment and high mortality. There 
is an increased incidence among patients with inflammatory 
bowel disease, especially young male patients under 35 
years old and on combination therapy (thiopurine and anti-
TNF-α). We describe a case of HSTCL in a young male patient 
with stenosing ileal Crohn’s disease on azathioprine mono-
therapy for 4.8 years admitted to our hospital with intra- 
abdominal sepsis. Despite chemotherapy, the patient even-
tually died 1 month after the diagnosis. Through a literature 
review, we identified 18 additional cases of HSTCL in Crohn’s 
disease patients that had only been treated with thiopurine 
monotherapy. The authors intend to highlight the rarity of 
this diagnosis especially with azathioprine monotherapy 
and the diagnostic challenge in a case that presented with 
intra-abdominal sepsis.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
O linfoma de células T hepatoesplénico é um tipo raro e 
agressivo de linfoma não Hodgkin associado a fraca re-
posta à terapêutica e elevada mortalidade. A sua incidên-
cia está aumentada em doentes com doença inflamatória 
intestinal, particularmente jovens com menos de 35 anos, 
do sexo masculino e em terapêutica combinada com tio-
purinas e inibidores TNF-α. Apresentamos o caso de um 
linfoma T hepatoesplénico num homem jovem com 
doença de Crohn ileal estenosante sob monoterapia com 
azatioprina há 4,8 anos, admitido no nosso hospital num 
contexto de sépsis de ponto de partida intraabdominal. 
Apesar da quimioterapia o doente acabou por falecer 1 
mês após o diagnóstico. Numa revisão da literatura, os 
autores identificaram 18 casos adicionais de linfoma T 
hepatosplénico em doentes com doença de Crohn trata-
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dos apenas com tiopurinas em monoterapia. Os autores 
pretendem destacar a raridade do diagnóstico, especial-
mente no contexto de azatioprina em monoterapia e o 
desafio diagnóstico num caso que se apresentou com 
sépsis intra-abdominal.
© 2018 Sociedade Portuguesa de Gastrenterologia  
Publicado por S. Karger AG, Basel
Introduction
Hepatosplenic T-cell lymphoma (HSTCL) is a very 
rare (< 1%) and aggressive peripheral T-cell non-Hodgkin 
lymphoma [1]. Even though the majority of cases arise de 
novo, approximately 30% of cases occur in the setting of 
chronic immunosuppression and chronic antigen stimu-
lation, as is the case in inflammatory bowel disease (IBD) 
[2]. Young men under 35 years with Crohn’s disease who 
are treated with thiopurines and anti-TNF for at least 2 
years are at higher risk [1].
We report the case of a 25-year-old male with a 5-year 
history of stenosing ileal Crohn’s disease on azathioprine 
monotherapy for 4.8 years and the challenging diagnosis 
of HSTCL in the setting of intra-abdominal sepsis.
Case Presentation
The subject of this report is a 25-year-old leukodermic male 
with a diagnosis of stenosing ileal Crohn’s disease for 5 years (A2 
L1 B2 in the Montreal classification). He had a surgical history of 
a stricturoplasty and segmental enterectomy for a stenosis in 2012 
without complications.
The patient had been treated with azathioprine (2.5 mg/kg) for 
4.8 years. Prior to initiation of thiopurines, the patient was submit-
ted to EBV screening, which revealed that the patient was immune 
to EBV (IgG positive, IgM negative). He had also previously taken 
iron and vitamin B12 supplementation. No other personal, rele-
vant background, medical, or family history was found. On his last 
medical appointment, before hospital admission, the patient had 
been asymptomatic and the blood tests had been normal. His last 
ileocolonoscopy (1 month prior to admission) had demonstrated 
a small ulceration in the ileocecal valve, and the patient had been 
started on mesalamine 3 g/day plus budesonide 9 mg/day.
The patient presented to the emergency department with a 
7-day history of fever and unspecific lower abdominal pain. On 
physical examination, he was febrile (39  ° C) and polypneic and had 
a blood pressure of 117/70 mm Hg and a heart rate of 60 bpm. Ab-
dominal examination showed tenderness in his lower right abdo-
men and splenomegaly, but there were no signs of peritoneal irri-
tation. No lymphadenopathies were noted. A complete blood 
count revealed a normal white blood cell count, anemia (9.4 g/dL), 
and thrombocytopenia (136,000 µL). Blood chemistry showed el-
evated C-reactive protein (75.10 mg/dL) and lactate dehydroge-
nase (LDH) (2,177 U/L). Levels of liver transaminase, bilirubin, 
urea, and creatinine were normal.
An abdominal computed tomography scan revealed hepato-
megaly, splenomegaly (Fig. 1) with infarct, and a 5-cm abscess ad-
jacent to a small bowel surgical suture. No lymphadenopathies 
were evident. The patient then underwent surgical drainage of the 
abscess without immediate postoperative complications. Four 
days after the surgery, the patient was admitted to the intensive 
care unit with septic shock and multiorgan dysfunction (hemato-
logical, renal, hepatic, and respiratory) due to infection of his sur-
Fig. 1. Abdominal computed tomography image (sagittal view) 
showing hepatomegaly and splenomegaly (18 cm).
Fig. 2. Bone biopsy with hematoxylin and eosin staining. The im-
age shows diffuse interstitial bone marrow infiltration by medium-
sized lymphoid cells (arrows).
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gical wound with methicillin-resistant Staphylococcus aureus. De-
spite directed antibiotic therapy, the patient’s clinical condition 
did not improve and he remained febrile with bicytopenia (hemo-
globin 6.9 g/dL, platelets 108,000/µL), elevated C-reactive protein 
levels (164 mg/dL), elevation of aminotransferases (AST 95 U/L, 
ALT 202 U/L) and LDH (7,472 U/L), hypoalbuminemia (24 g/L), 
hyperbilirubinemia (3.53 mg/dL), hypertriglyceridemia (247 mg/
dL), hyperferritinemia (> 7,500 ng/mL), and β2-microglobulin 
(4.94 mg/L). A bone marrow biopsy showed diffuse interstitial in-
filtration by medium-sized lymphoid cells of the T-cell phenotype 
(CD3+) with irregular nuclei and presence of a nucleolus (Fig. 2–4). 
Flow cytometry showed expression of CD2, CD3, CD7, and T-cell 
receptor-γ/δ. Together, these findings were consistent with γ/δ-
HSTCL.
After resolution of the infectious state, the patient underwent 
2 cycles of chemotherapy with cyclophosphamide, hydroxydauno-
rubicin, vincristine, and prednisolone (CHOP) with no response. 
A second line of chemotherapy with etoposide, cisplatin, cytara-
bine, and methylprednisolone (ESHAP) was started, but the pa-
tient eventually died as a result of severe bleeding complications 
only 1 month after the diagnosis.
Discussion
The diagnosis of HSTCL in Crohn’s disease may be 
challenging due to the overlap of manifestations of both 
conditions, especially in immunosuppressed patients. In 
our case, the diagnosis was further delayed due to the con-
comitant presentation of sepsis. Until the diagnosis of 
HSTCL, the patient’s fever, bicytopenia, and splenomeg-
aly (and infarct) were initially interpreted as related to the 
septicemia. These findings could also explain high LDH 
levels. A high level of suspicion is therefore needed in this 
subset of patients.
We searched the PubMed database using the terms 
“hepatosplenic T-cell lymphoma,” “inflammatory bowel 
disease,” and “Crohn’s disease.” We also reviewed the 
bibliographies of the most relevant articles.
Including our case, we identified 19 cases of HSTCL in 
Crohn’s disease that had only been treated with thiopu-
rines in monotherapy (anti-TNF-naïve patients) (Table 
1) [3–13]. Of the 19 patients, 15 were men (79%), 2 were 
women, and 2 were not specified (NS). The median age at 
diagnosis was 23.5 years (range 13–72). Of the 10 cases 
that reported the duration of thiopurine therapy before 
HSTCL, the median treatment duration was 5 years 
(range < 1 to 8). Presenting clinical features were specified 
for 11 patients. Splenomegaly was the most dominant 
clinical feature, present in all 11 patients (7 also had hep-
atomegaly), followed by constitutional symptoms (fever, 
fatigue, and night sweats), which were present in 8 pa-
tients (73%). Of the 11 cases, only 7 had reported blood 
counts, and all presented with cytopenia. Thrombocyto-
penia was present in all patients, followed by anemia 
(86%) and leukopenia (71%). Treatment options were 
available for 16 patients. Different chemotherapy modal-
ities were used aiming for a curative allogenic stem cell 
transplant; however, due to the fast and aggressive course 
of the disease, the overall survival rate was very low. An 
exception is a unique case of a 27-year-old female with 
Fig. 3. Bone biopsy image with CD3 antibody staining (immuno-
histochemistry) revealing the T-cell phenotype (CD3+ orange 
stain).
Fig. 4. Bone biopsy image revealing irregular nuclei and the pres-
ence of a nucleolus (orange stain) in T-cell lymphoid cells.
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Crohn’s disease on thiopurine for 5 years who was treated 
for 9 months with interferon-α monotherapy and achieved 
a 20-month follow-up remission free. In our case, the 
therapeutic options were remarkably limited due to the 
patient’s poor condition and severe cytopenia.
There has been some debate as to whether IBD, by it-
self, could potentially increase the risk of lymphomas, 
more specifically of HSTCL. It has been speculated that 
in HSTCL, underlying immunodysregulatory disorders 
could lead to excessive antigenic stimulation of γδ T cells 



















Index case 25; M 5 4.8; AZA Fever, hepatosplenomegaly, 
anemia, thrombocytopenia, liver 
test abnormalities
CHOP, ESHAP <1/dead
2017 [3] 21; M 13 NS; 6-MP NS CHOP, ESHAP, DHAP, 
pentostatin, alemtuzumab
7/dead
2017 [3] 31; M NS NS; 6-MP NS Hyper-CVAD 3/dead
2017 [3] 18; M 5 2; AZA NS Hyper-CVAD, MTX, AraC, 
etoposide, ifosfamide, autologous 
SCT
50/alive
2017 [3] 38; M 16 NS; 6-MP NS CHOP, DHAP, ICE 11/dead
2017 [3] 72; F NS NS; AZA NS CHOP 1/alive
2014 [5] 39; M 13 4; AZA Hepatosplenomegaly, leukopenia DHAC, SMILE NS/dead
2014 [5] 42; M 13 NS; AZA Fever, weight loss, malaise, 
abdominal pain, 
hepatosplenomegaly, pancytopenia
Hyper-CVAD NS/dead AZA cumulative dose 440 g
2013 [4] NS; M NS 7; AZA Fever, splenomegaly, 
thrombocytopenia, liver test 
abnormalities
Asparaginase-containing high-dose 
chemotherapy, allogenic SCT 
NS/dead Died on day 381 after transplant 
due to sepsis; postmortem analysis 
showed no evidence of lymphoma
2013 [6] 18; M NS <1; AZA, 6-MP NS NS 7/dead AZA cumulative dose 1,450 mg
2013 [6] 13; M NS NS; 6-MP NS NS NS
2010 [7] 18; M 5 5; 6-MP Fever, night sweats, splenomegaly, 
anemia, thrombocytopenia
Pentostatin, ICE, autologous SCT 7/dead
2010 [8] 19; M NS 6; AZA Fatigue, abdominal fullness, 
leukopenia, splenomegaly
Chemotherapy (NS), splenectomy <4/dead
2010 [8] 22; M NS 8; 6-MP Fatigue, fever, night sweats, 
abdominal pain, splenomegaly
Chemotherapy (NS), allogenic SCT NS/alive
2008 [10] 27; F NS 5; AZA Fever, night sweats, 
hepatosplenomegaly, 
pancytopenia, liver test 
abnormalities
Interferon-α 20/alive
2006 [9] 18; M 9 6; AZA Pancytopenia, fever, 
hepatosplenomegaly
IVE, ESHAP, splenectomy, 
alemtuzumab + fludarabine, 
pentostatin, allogenic SCT
NS/dead Died of aggressive B-cell 
posttransplant 
lymphoproliferative disease
2006 [11] NS NS NS; 6-MP Splenomegaly, NS Chemotherapy NS NS/NS
2003 [12] 35; M 15 5.5; AZA Night sweats, hepatosplenomegaly, 
petechiae, anemia, 
thrombocytopenia, liver test 
abnormalities
High-dose CHOP and ESHAP NS/dead
1998 [13] NS; NS NS 4; AZA NS NS NS/dead
6-MP, mercaptopurine; AraC, cytosine arabinoside; AZA, azathioprine; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; DHAC, dexamethasone, carboplatin, 
and cytarabine; DHAP, dexamethasone, cytarabine, and cisplatin; ESHAP, etoposide, cisplatin, cytarabine, and methylprednisolone; F, female; Hyper-CVAD, hyper fractionated 
cyclophosphamide, vincristine, doxorubicin, and dexamethasone; ICE, ifosfamide, carboplatin, and etoposide; IVE, ifosfamide, epirubicin, and etoposide; M, male; MTX, methotrexate; 
NS, not specified; SCT, stem cell transplant; SMILE, methotrexate, ifosfamide, L-asparaginase, and etoposide.
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and polyclonal γδ T-cell expansion. Further transforming 
genetic events could culminate in HSTCL [3]. However, 
no cases of HSTCL in IBD therapy-naïve patients have 
been reported in the literature [14]. 
It is well established by now that there is a higher risk 
of lymphoma in IBD patients on thiopurines [15]. Fol-
lowing absorption, their metabolite – 6-thioguanine – ac-
cumulates in bone marrow, immune cells (such as lym-
phocytes), and epithelial tissue, where they inhibit purine 
synthesis, cause DNA and RNA damage, and eventually 
lead to malignant proliferation [16]. Although this cyto-
toxic effect has been thought to be the main carcinogenic 
pathway, a thiopurine-specific contribution has been 
postulated [17].
In a cross-sectional study, there was in vivo evidence 
that chronic thiopurine treatment was associated with a 
dose-dependent increase in the frequency of somatic mu-
tations in tissue with a high accumulation of 6-thiogua-
nine [17]. Also, cytogenic changes have been reported in 
a dose-dependent manner with thiopurines, more spe-
cifically with chromosome 7. In a systematic review of 
cytogenic changes in HSTCL patients with IBD, altera-
tions of isochromosome 7q, aberrations of chromosomes 
8 and 13, and deletion of the Y chromosome were found 
[18]. The last finding is of particular interest, since HST-
CL predominantly affects male patients.
The largest population-based cohort study on thiopu-
rine use and lymphoproliferative disorders in IBD pa-
tients showed that patients who received thiopurines 
were 5 times more likely to develop a lymphoproliferative 
disorder [19]. These findings were also validated in a re-
cent meta-analysis that included 8 population-based 
studies and 10 referral studies [20]. Combination therapy 
with anti-TNF further raises the HSTCL risk [15]. In men 
younger than 35 years, where the risk seems higher, as 
with our case, the absolute risk is estimated to be 1: 7,404 
on monotherapy with thiopurine and 1: 3,534 on combi-
nation therapy, with 80% of the cases occurring after 2 
years of combination therapy [1]. These findings support 
the current recommendations to limit the duration of 
combined treatment to 2 years for young males [15]. No 
formal recommendations regarding duration limitation 
of monotherapy with azathioprine exist for this subgroup 
of patients, even though awareness regarding therapies 
longer than 1 year has been advised [1].
Conclusions
With this case report, the authors intended to high-
light the rarity of this diagnosis, especially for patients on 
monotherapy with azathioprine, as well as the diagnostic 
challenge in a patient that presented with intra-abdomi-
nal sepsis. Further understanding of the mechanisms that 
lead to HSTCL might be helpful to minimize the risks of 
this malignancy in IBD patients.
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